Investigating a key enzyme's role in diabetic retinopathy
Official title: Soluble guanylate cyclase in diabetic retinopathy
Funded at Johns Hopkins University · NIH-11037977 · Data updated 2026-11-12
This study is looking at how a specific protein might help protect your eyes from damage caused by diabetes, with the hope of finding new treatments to prevent vision loss from diabetic retinopathy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | March 1, 2024 |
| Project end | December 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $473,552 |
| NIH project number | 5R01EY035549-02 |
| Project ID | NIH-11037977 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with diabetic retinopathy, particularly those in the early stages of the disease.
✕Less likely to help
Patients with advanced diabetic retinopathy who have already lost significant vision may not benefit from this research.
What this research studies
This research focuses on diabetic retinopathy, a leading cause of blindness, by exploring the role of soluble guanylate cyclase (sGC) in the disease's progression. The study aims to identify how oxidative stress affects sGC and its potential as a therapeutic target. Using both laboratory and animal models, researchers will investigate the neuroprotective effects of sGC activators, which could lead to new treatment options for patients with diabetic retinopathy. The goal is to enhance understanding of the disease and develop strategies to prevent vision loss.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that prevent or slow the progression of diabetic retinopathy, potentially preserving vision for many patients.
How similar studies have gone: Previous research has shown promising results with similar approaches targeting soluble guanylate cyclase in other conditions, indicating potential for success in this area.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Duh, Elia J — Johns Hopkins University
- Study coordinator: Duh, Elia J
Related research
Other NIH-funded projects on the same topics.
-
Integrative multi-omics to understand diabetic retinopathy
A doctor-scientist team will study blood markers and genetic signals to see why diabetic retinopathy happens and how it affects Hispanic/Latino people.
-
Smartphone retinal imaging for diabetic eye disease in Egypt
This project uses a low-cost smartphone camera and AI to find signs of diabetic eye damage in adults with diabetes in Egypt.
-
Retinal Cell Loss in Diabetic Retinopathy
This project looks at how mitochondrial problems and a specific kind of cell death called ferroptosis may cause retinal cells to die in people with diabetes-related eye disease.
-
Redox-triggered REDD1 blockers for diabetic retinopathy
A research project tests new ways to stop a stress protein (REDD1) from causing vision problems in people with diabetic retinopathy.
-
Ultrafast eye imaging to detect and track diabetic retinopathy
A doctor-science team is developing ultra-fast eye scans to better see tiny blood vessels in people with diabetic retinopathy, helping catch changes early and guide treatment.
-
Practical device to automatically track abnormal retinal blood vessel growth in diabetic eye disease
A new, easier-to-use imaging device aims to automatically detect and monitor abnormal retinal blood vessel growth in people with diabetic retinopathy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.